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ABSTRACT 
Phosphodiesterase (PDE) IV inhibitors have been shown to inhibit various 
inflammatory reactions in pulmonary diseases such as bronchial asthma and chronic 
obstructive lung diseases (COPD).  However, there have been no studies evaluating the 
effect of PDE IV inhibitors on airway fibrosis, which is a critical feature of airway 
remodeling in asthma and COPD.  We therefore examined whether ONO-EF-345 
(ONO), a PDE IV inhibitor, affected the function of lung fibroblasts.  ONO suppressed 
TGF-β-induced type I collagen (COL1) mRNA expression in lung fibroblasts and also 
inhibited TGF-β-induced α- smooth muscle actin (SMA) protein expression.  ONO did 
not affect Smad2 phosphorylation or Smad7 expression.  However, ONO reduced JNK 
and p38 activation, which regulates TGF-β-induced COL1 expression.  These results 
indicate that PDE IV inhibitors exert anti-fibrotic effects through the JNK and/or p38 
pathways. 
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INTRODUCTION 
Asthma and COPD are chronic 
inflammatory diseases of the conducting 
airways and lung parenchyma that are 
characterized by airflow obstruction.  
Accumulating evidence indicates that the 
structure of the airway wall is abnormal in 
asthmatic and COPD patients (Jeffery, 
2001), and the term “airway remodeling” 
is now widely used for these structural 
changes.  It is frequently assumed that 
airway remodeling is induced as a 
consequence of repeated injury and repair 
attributed to chronic inflammation within 
the airway wall (Bousquet et al., 2000).  
However, the cellular and molecular 
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mechanisms underlying the remodeling 
process are not fully understood, and the 
precise relationship between the 
remodeling and inflammatory components 
in asthma and COPD still remains 
controversial (Jeffery, 2001). 
 
The features of structural remodeling in 
airways include subepithelial fibrosis, 
myofibroblast accumulation, airway 
smooth muscle hyperplasia and 
hypertrophy, goblet cell hyperplasia, and 
epithelial disruption.  Airway fibrosis, 
which is an irreversible component of 
airway obstruction (Gabbrielli et al., 
1994), involves the activation of 
myofibroblasts and the increased 
deposition of ECM constituents such as 
collagen and fibronectin (Redington, 
2000).  TGF-β induces the expression of 
collagen type I (COL1) and also 
stimulates the differentiation of fibroblasts 
into myofibroblasts.  A significant 
correlation has been observed between 
TGF-β expression and the degree of 
airway fibrosis in both asthma and COPD 
(Antonio et al., 1997), supporting the 
concept that TGF-β plays an important 
role in the development of airway fibrosis. 
 
Recent evidence suggests that 3’5’-cyclic 
adenosine monophosphate (cAMP) 
functions as a second messenger which 
modulates fibroblast activation (Yano et 
al., 2006; Liu et al., 2004; Huang et al., 
2006).  The cAMP concentration is 
regulated by adenyl cyclase, which 
produces cAMP, and phosphodiesterases 
(PDEs), which hydrolyse cAMP.  PDEs 
comprise 11 pharmacologically distinct 
families of metallophosphohydrolases that 
degrade cAMP and/or 3’5’-cyclic 
guanosine monophosphate (cGMP), which 
results in the inactivation of their function.  
Among the members of the PDE family, 
PDE IV is regarded as a critical molecule 
in regulating the inflammatory cells 
associated with asthma and COPD 
(Lipworth, 2005).  PDE IV is encoded by 
four genes and specifically hydrolyses 
cAMP.  Recently, several PDE IV 
inhibitors have been developed, and 
cilomilast and roflumilast have already 
been evaluated in clinical trials. 
 
Despite numerous studies on the 
anti-inflammatory effects of PDE IV 
inhibitors, few studies have assessed the 
direct effects of PDE IV inhibitors on 
airway remodeling.  It has recently been 
demonstrated that the inhibition of PDE 
IV reduces mucin production in bronchial 
cells (Mata et al., 2005).  We herein 
investigated whether a PDE IV inhibitor, 
ONO-EF-345 (ONO) described as 
ONO-12(b) in (Ochiai H, 2004), directly 
regulates lung fibroblast COL1 synthesis 
and α-SMA expression. We also 
investigated the mechanism of the 
anti-fibrotic effects of PDE IV inhibitors. 
 
MATERIALS AND METHODS 
Materials. 
Human Transforming growth factor-β 
(TGF-β) was purchased from Sigma (St 
Louis, MO).  SB203580 and SP600125 
were purchased from Calbiochem (San 
Diego, CA).  ONO-EF-345 (Ochiai H, 
2004), a PDE IV inhibitor, was provided 
by ONO Pharmaceutical Co., Ltd (Osaka, 
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JAPAN). Isogen® was purchased from 
Nippon Gene (Tokyo, Japan).  
Antibodies against α-smooth muscle actin 
(α-SMA) and β-actin were purchased 
from American Research Products, Inc., 
(Belmont, MA) and MP Biochemicals 
(Irvine, CA), respectively.  Antibodies 
against phospho-Smad2 and total Smad2 
were obtained from Cell signaling 
technology (Beverly, MA). Fast Activated 
Cell-based ELISA (FACE™) Kits were 
purchased from Active Motif (Carlsbad, 
CA). 
 
Cell culture. 
Normal human lung fibroblast (NHLF) 
cells (Sanko Jyunyaku, Tokyo, Japan) 
were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 100 
U/ml penicillin, and 10 µg/ml 
streptomycin at 37°C in a humidified 
atmosphere of 95% air and 5% CO2.  
NHLF cells between passages 4 and 8 
were used in the experiments. 
 
TGF-β experiments. 
NHLF cells were seeded on a 6-well dish 
and allowed to incubate overnight.  After 
reaching subconfluence, the cells were 
starved for 24 h and were then treated 
with 10 ng/ml TGF-β. In pretreatment 
experiments, the cells were administered 
ONO at a concentration of 1 nM to 1 μM 
2 h before TGF-β stimulation. ONO has a 
specific PDE inhibitory activity and no 
cytotoxicity at these concentrations 
(Ochiai H, 2004). In posttreatment 
experiments, the cells were first incubated 
with TGF-β for 48 h and were then 
stimulated by TGF-β with or without 
ONO. In some experiments, the cells were 
preincubated with SB203580, a specific 
p38 inhibitor, or SP600125, a specific 
JNK inhibitor, for 30 min before TGF-β 
administration. 
 
Real-time PCR. 
The cells were treated with TGF-β for 24 
h before the extraction of total RNA from 
each well using Isogen® according to the 
manufacturer’s instructions.  One 
microgram of total RNA was 
reverse-transcribed with SuperScripts III 
reverse transcriptase (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s 
instructions.  Real-time PCR was then 
conducted using ABI PRISM 7900 
(Applied Biosystems, Foster City, CA) 
based on the ability of the 5’ nuclease 
activity of Taq polymerase to cleave a 
labeled fluorogenic hybridization probe 
during DNA chain extension.  The 
sequence-specific primers and probe 
mixtures for human COL1, human Smad7, 
and human GAPDH were obtained from 
TaqMan® Gene Expression Asssays 
(Applied Biosystems, Foster City, CA). 
The relative mRNA expression levels of 
COL1 were normalized against that of the 
GAPDH gene from the same preparations. 
 
Western blotting. 
The cells were seeded on a 6-well dish. 
Before reaching confluence, the cells were 
starved for 24 h, then stimulated by 
TGF-β with or without ONO.  The cells 
were lysed with RIPA buffer as described 
previously (Inoue et al., 2005).  Samples 
were separated on 10% 
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SDS-polyacrylamide gels and transferred 
to polyvinylidene difluoride membranes 
(Millipore, Billerica, MA).  The 
membranes were incubated with primary 
antibodies against α-SMA (American 
Research Products, Inc., Belmont, MA), 
phospho-Smad2, or total Smad2 (Cell 
signaling technology, Beverly, MA).  
The membranes were then incubated with 
secondary HRP-conjugated antibodies.  
The membranes were visualized by a 
chemiluminescence reagent (Perkin-Elmer 
Life Science, Boston, MA), and the image 
was obtained by exposure to X-ray films.  
The relative protein loading was 
normalized after the membrane was 
stripped and reprobed with anti-β-actin 
antibody (MP Biochemicals, Irvine, CA). 
 
Phosphorylation of JNK and p38. 
The amounts of JNK and p38 
phosphorylation were determined by 
FACE™ Kits. Briefly, NHLF cells were 
cultured in 96-well plates at a density of 
3,000 cells per well and stimulated by 
TGF-β with or without ONO. Following 
stimulation, the cells were rapidly fixed 
with 4% formaldehyde to preserve 
activation-specific protein modifications.  
Each well was then incubated with 
primary antibodies against phospho-JNK, 
phospho-p38, total JNK or total p38, and 
the cells were subsequently incubated 
with secondary HRP-conjugated 
antibodies and developing solution. The 
absorbance was read on a 
spectrophotometer at 450 nm with an 
optional reference wavelength of 655 nm. 
The relative number of cells in each well 
is then determined using the Crystal Violet 
solution. 
 
Statistics. 
Data are expressed as the means ± SEM. 
The statistical significance of the 
differences was evaluated by ANOVA. 
Values of p <0.05 were considered to be 
statistically significant. 
 
RESULTS 
ONO decreases TGF-β-induced COL1 
mRNA expression in lung fibroblasts. 
TGF-β is a potent inducer of COL1 and is 
involved in the pathogenesis of airway 
fibrosis in asthma and COPD (Takizawa 
et al., 2001; Postma et al., 2006). To 
investigate the inhibitory effect of ONO 
on TGF-β-induced COL1 mRNA 
expression, NHLF cells were treated with 
TGF-β in the presence or absence of ONO. 
The amount of COL1 mRNA expression 
was determined by the real-time PCR 
method. As expected, we observed a 
6-fold increase in TGF-β-enhanced COL1 
mRNA expression in comparison to the 
control. ONO decreased TGF-β-induced 
COL1 mRNA expression in a 
dose-dependent manner (Fig.1A). 
 
ONO decreases TGF-β-induced α-SMA 
protein expression in NHLF cells.  
The transformation of fibroblasts into 
myofibroblasts, a prominent feature of 
fibroblast activation, is often observed in 
airway fibrosis. α-SMA is a myofibroblast 
marker that is also induced by TGF-β. 
Therefore, we next investigated the effect 
of ONO on TGF-β-induced α-SMA 
expression. NHLF cells were treated with 
TGF-β in the presence or absence of ONO 
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for 48 h, and the amount of α-SMA 
protein was determined by Western 
blotting. TGF-β markedly enhanced 
α-SMA protein expression. ONO 
significantly decreased TGF-β-induced 
α-SMA expression in a dose-dependent 
manner (Fig.1B). 
 
 
 
 
Figure 1: Effects of ONO on TGF-β-induced COL1 mRNA expression and 
α-SMA protein expression. The cells were treated with 10 ng/ml TGF-β in the 
presence or absence of the indicated concentrations of ONO. (A) The amount of 
COL1 mRNA expression was evaluated by real-time PCR. The relative levels of 
COL1 mRNA expression were normalized by assessing the ratio of COL1 
against GAPDH. Data are expressed as the ratio of the control value of 
COL1mRNA/GAPDH mRNA from the vehicle treatment. Data represent the 
means ± SEM of results from three independent experiments. *p <0.0001 control 
vs. TGF-β, **p <0.05 TGF-β vs. TGF-β plus ONO. (B) The amount of 
TGF-β-induced α-SMA was determined by Western blotting. The result is 
representative of three separate experiments with similar results. 
 
Posttreatment with ONO inhibits 
TGF-β-induced COL1 mRNA expression 
and α-SMA protein expression in NHLF 
cells. 
In this study we demonstrated that 
pretreatment with ONO inhibited 
TGF-β-induced COL1 mRNA expression 
and α-SMA protein expression in NHLF 
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cells. However, in clinical practice, the 
process of airway fibrosis has already 
commenced before treatment is initiated. 
Therefore, we investigated whether 
treatment of NHLF cells with ONO after 
their stimulation with TGF-β also exerted 
inhibitory effects. Treatment with ONO 
even 48 h after TGF-β stimulation 
significantly decreased TGF-β-induced 
COL1 mRNA expression and α-SMA 
protein expression (Fig.2). 
 
 
 
Figure 2: Effects of posttreatment with ONO on TGF-β-induced COL1 mRNA 
expression and α-SMA protein expression. After 48 h stimulation with 10 ng/ml 
TGF-β, NHFL cells were treated with TGF-β in the various concentrations of 
ONO. (A) The amount of COL1 mRNA expression was evaluated by real-time 
PCR. The relative levels of COL1 mRNA expression were normalized by 
assessing the ratio of COL1 against GAPDH. Data are expressed as the ratio of 
the control value of COL1mRNA/GAPDH mRNA from the vehicle treatment. 
Data represent the means ± SEM of results from three independent experiments. 
*p <0.05 TGF-β vs. TGF-β plus ONO. (B) The amount of TGF-β-induced α-SMA 
was determined by Western blotting. The result is representative of three 
separate experiments with similar results. 
 
ONO does not inhibit the TGF-β-mediated 
phosphorylation of Smad2 in NHLF cells  
Many of the effects of TGF-β are 
mediated through Smad2/3 pathways 
(Derynck et al., 2003). To determine the 
extent of Smad2 phosphorylation by 
TGF-β, NHLF cells were treated with 
TGF-β in the presence or absence of ONO, 
and a Western blot analysis was conducted. 
As shown in Fig. 3A, TGF-β markedly 
induced Smad2 phosphorylation. However, 
ONO did not decrease the amounts of 
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TGF-β-mediated Smad2 phosphorylation. 
 
Figure 3: Effects of ONO on TGF-β-mediated Smad signaling. (A) Effects on 
TGF-β-induced Smad2 phosphorylation. NHFL cells were treated with 10 ng/ml 
TGF-β in the presence or absence of 1 μM ONO. The amounts of 
phospho-Smad2 were evaluated by Western blotting. (B) Effects on 
TGF-β-mediated mRNA expression of Smad7. NHLF cells were treated with 10 
ng/ml TGF-β in the presence or absence of 1 μM ONO for 24 h. The relative 
levels of Smad7 mRNA expression were normalized by assessing the ratio of 
Smad7 against GAPDH. Data are expressed as the ratio of the control value of 
Smad7 mRNA/GAPDH mRNA from the vehicle treatment. Data represent the 
means ± SEM from three independent experiments. * p <0.001 control vs. TGF-β, 
N.S. TGF-β vs. TGF-β plus ONO. N.S. stands for Not Significant. 
 
 
ONO does not affect the TGF-β-induced 
upregulation of Smad7 mRNA expression 
in NHLF cells. 
Smad7 is an intracellular antagonist for 
TGF-β signaling and inhibits Smad2 
activation (Derynck et al., 2003).  To 
investigate whether ONO could affect the 
TGF-β-mediated Smad7 pathway, NHLF 
cells were treated with TGF-β in the 
presence or absence of ONO for 24 h. The 
amounts of Smad7 mRNA were 
determined by real- time PCR. As shown 
in Fig.3B, TGF-β increased the expression 
of Smad7 mRNA.  However, ONO did 
not affect the TGF-β-induced upregulation 
of Smad7 mRNA expression. Collectively, 
these results indicate that ONO does not 
affect TGF-β-mediated Smad pathways. 
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Figure 4: Effects of ONO on TGF-β-mediated JNK and p38 activation. NHFL 
cells were treated with 10 ng/ml TGF-β in the presence or absence of SP600125, 
a specific JNK inhibitor, SB203580, a specific p38 inhibitor, or ONO. (A) The 
amount of COL1 mRNA expression was evaluated by real-time PCR. The 
relative levels of COL1 mRNA expression were normalized by assessing the 
ratio of COL1 against GAPDH. Data are expressed as the ratio of the control 
value of COL1mRNA/GAPDH mRNA from the vehicle treatment. Data represent 
the means ± SEM of results from three independent experiments. *p <0.0001 
control vs. TGF-β, **p <0.0001 TGF-β vs. TGF-β plus SP600125 or SB203580.  
(B, C)  The levels of TGF-β-induced JNK (B) and p38 (C) phosphorylation were 
determined by FACE™ ELISA Kits. The relative levels of phosphorylated JNK 
and p38 were normalized by assessing the ratio against total JNK and p38, 
respectively. Data are expressed as the ratio of the control value of 
phosphorylated JNK and p38/total JNK and p38, respectively, from the vehicle 
treatment. Data represent the means ± SEM of results from six and four 
independent experiments, respectively. *p <0.0001 control vs. TGF-β, **p <0.05 
TGF-β vs. TGF-β plus ONO. 
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ONO inhibits the TGF-β-mediated 
phosphorylation of JNK and p38 in NHLF 
cells 
In addition to classical Smad pathways, 
mitogen-activated protein kinase (MAPK) 
pathways function as downstream of 
TGF-β signaling (Derynck et al., 2003). 
We and other investigators have shown 
that TGF-β induces JNK and p38 
phosphorylation and that TGF-β induces 
COL1 mRNA expression and α-SMA 
expression via the JNK and/or p38 
pathways (Inoue et al., 2005; Hu et al., 
2006). To confirm that inhibition of JNK 
or p38 suppresses TGF-β-induced COL1 
mRNA expression, we used selective and 
specific inhibitors of JNK and p38. As 
expected, both inhibitors significantly 
decreased TGF-β-induced COL1 mRNA 
expression (Fig. 4A). Then we determined 
whether ONO could block the 
TGF-β-mediated JNK and p38 pathways. 
The cells were treated with TGF-β in the 
presence or absence of ONO, and the 
cell-based ELISA system for detecting the 
phosphorylation of JNK and p38 was 
conducted. As shown in Fig. 4B and 4C, 
TGF-β induced the phosphorylation of 
JNK and p38. ONO significantly 
suppressed the extent of TGF-β-induced 
JNK and p38 phosphorylation. 
 
DISCUSSION 
PDE IV inhibitors have been known to 
exert anti-inflammatory effects. However, 
the direct effect of PDE IV inhibitors on 
airway fibrosis, one of the critical features 
of airway remodeling, had not previously 
been assessed. Our examination of 
whether ONO, a specific PDE IV inhibitor, 
affected the function of lung fibroblasts 
revealed that it inhibited TGF-β-induced 
COL1 mRNA expression in lung 
fibroblasts and also reduced 
TGF-β-induced α-SMA protein. However, 
ONO did not affect Smad2 
phosphorylation or Smad7 expression 
induced by TGF-β. ONO suppressed JNK 
and p38 phosphorylation, which regulate 
TGF-β-induced COL1 mRNA expression 
and α-SMA protein expression. 
Collectively, these results indicate that 
PDE IV inhibitors exert anti-fibrotic 
effects, at least partly, through the JNK 
and/or p38 pathways. 
 
We demonstrated the anti-fibrotic effects 
of ONO on NHLF cells in this study. We 
also investigated whether roliplam, 
another PDE IV inhibitor, also exerts an 
inhibitory effect on TGF-β-induced COL1 
mRNA expression with the same results 
(personal observation).  Our findings 
indicate that ONO suppresses 
TGF-β-induced COL1 mRNA expression 
as a specific PDE IV inhibitor via the 
cAMP pathway.  This result is supported 
by previous reports demonstrating that 
PGE2 and other adenylyl cyclase 
activators, which increase intracellular 
cAMP, inhibit collagen synthesis (Liu et 
al., 2004; Huang et al., 2006). It has also 
been demonstrated that cAMP inhibits 
myofibroblast differentiation (Kolodsick 
et al., 2003). It is therefore likely that 
ONO also reduces TGF-β-induced 
α-SMA expression through the cAMP 
pathway. Collectively, these results 
support the concept of the anti-fibrotic 
effects of PDE IV inhibition via the cAMP 
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pathway. 
 
Smad pathways have been recognized as 
the main mediator of TGF-β-induced gene 
expression, including the expression of 
COL1 (Derynck et al., 2003). The 
phosphorylation of Smad2/3 causes it to 
associate with Smad4. The complex 
translocates into the nucleus, where it 
regulates transcriptional responses 
together with additional DNA binding 
cofactors. Inversely, Smad7 regulates 
fibrotic reactions induced by TGF-β 
(Nakao et al., 1999). Smad7 is induced by 
TGF-β to negatively regulate TGF-β 
signaling by interrupting Smad2/3 
activation. However, ONO did not 
influence either the Smad7 gene 
expression or Smad2 phosphorylation in 
this study. These results are consistent 
with a previous report demonstrating that 
pentoxifylline, a xanthine derivative that 
increases intracellular cAMP, does not 
interfere with TGF-β signaling to 
Smad2/3 activation controlled by Smad7 
(Lin et al., 2005). Furthermore, the cAMP 
pathway has been demonstrated to inhibit 
TGF-β-induced Smad-dependent 
transcription by the disruption of 
transcription cofactor binding (Schiller et 
al., 2003). These reports support our 
results that the suppressive effects of PDE 
IV inhibitors on TGF-β signaling are not 
achieved through the direct modulation of 
Smad pathways. 
 
In addition to the classical Smad pathways, 
the MAPK pathways are involved in the 
TGF-β signaling (Derynck et al., 2003). 
MAPK regulates collagen gene expression 
by various stimuli, including TGF-β 
(Chen et al., 1999; Varela-Rey et al., 
2002). We have recently demonstrated that 
IL-10 inhibits TGF-β-induced COL1 
mRNA expression through the JNK and/or 
p38 pathways in lung fibroblasts, but not 
through the Smad pathways (Inoue et al., 
2005). It has also been shown that α-SMA 
expression induced by TGF-β is regulated 
by the JNK and/or p38 pathways  (Inoue 
et al., 2005; Hu et al., 2006). In our results, 
ONO suppressed TGF-β-induced JNK and 
p38 activation, which suggests that ONO 
exerts anti-fibrotic effects through the 
regulation of the JNK and/or p38 
pathways. Our results are consistent with 
the results of recent reports demonstrating 
that the JNK pathway is negatively 
regulated by the cAMP cascade (Delgado, 
2002), which is activated by the inhibition 
of PDE IV. 
 
Our results have also showed that even the 
treatment of cells with the PDE IV 
inhibitor after their stimulation by TGF-β 
resulted in the inhibition of 
TGF-β-induced COL1 mRNA expression 
and α-SMA expression. This finding is 
notable because in the clinical setting, 
airway remodeling and fibrosis have 
already commenced before treatment is 
started. Our results strongly indicate that 
PDE IV inhibition has suppressive as well 
as preventive effects on airway fibrosis. 
Furthermore, the administration of PDE 
IV inhibitors for the treatment of airway 
remodeling had a clinical advantage 
related to the two hypotheses about the 
mechanism of airway remodeling. Recent 
evidence suggests that airway remodeling 
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is induced as a consequence of repeated 
injury and repair attributed to chronic 
inflammation within the airway wall 
(Bousquet et al., 2000). Another equally 
plausible hypothesis is that the processes 
of chronic inflammation are distinct from 
those of remodeling (Jeffery, 2001). PDE 
IV inhibitors were originally regarded as 
anti-inflammatory drugs. Our data 
demonstrate that the inhibition of PDE IV 
also exerts direct anti-fibrotic effects. 
Therefore, PDE IV inhibitor 
administration could regulate airway 
remodeling by modulating both 
inflammation and fibroblast activation. 
To date, no simple or combination therapy 
is available for completely inhibiting 
airway inflammation and remodeling. 
Therefore, treatment with PDE IV 
inhibitors could be a feasible therapy for 
chronic airway diseases that are 
characterized by both inflammation and 
airway remodeling. Future studies are 
needed to determine whether these 
anti-fibrotic effects of PDE IV inhibitors 
are also observed in vivo. 
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